ANALYSIS OF CIRCULATING BIOMARKERS IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PORTOLA PHASE 2A STUDY EVALUATING ZETOMIPZOMIB, A SELECTIVE IMMUNOPROTEASOME INHIBITOR, IN PATIENTS WITH AUTOIMMUNE HEPATITIS (AASLD 2025) - Oct 8, 2025 - Abstract #4426; P2 | "In the PORTOLA Phase 2a study, zeto administration resulted in notable alterations in biomarker activity across both the innate and adaptive immune systems that correlated with clinically relevant biochemical responses in AIH. Circulating biomarker changes following zeto treatment were consistent with previous reports from clinical studies in patients with SLE. These findings provide intriguing starting points for further mechanistic studies and validation in the AIH population."
Biomarker • Clinical • P2a data • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • TGFB1
|
|
Janet Anderl1; Neel Anand1; David Bade1; Eric Lowe1; Kathryn Ray1; Brian Tuch1; Jennifer Whang1
|